53
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

      1 , 2 , 3 , 4 , 5 , 5 , 6 , 7 , 8 , 9 , 10 , 2 , 4 , 5 , 11 , 12 , 13 , 2 , 14 , 15 , 16 , 17 , 2 , 18 , 5 , 19 , 2 , 20 , 11 , 2 , 21 , 22 , 2 , 23 , 5 , 23 , 4
      Lancet (London, England)
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pathological complete response has been proposed as a surrogate endpoint for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (EFS), and overall survival (OS). We had four key objectives: to establish the association between pathological complete response and EFS and OS, to establish the definition of pathological complete response that correlates best with long-term outcome, to identify the breast cancer subtypes in which pathological complete response is best correlated with long-term outcome, and to assess whether an increase in frequency of pathological complete response between treatment groups predicts improved EFS and OS.

          Related collections

          Author and article information

          Journal
          Lancet
          Lancet (London, England)
          Elsevier BV
          1474-547X
          0140-6736
          Jul 12 2014
          : 384
          : 9938
          Affiliations
          [1 ] US Food and Drug Administration, Silver Spring, MD, USA. Electronic address: patricia.cortazar@fda.hhs.gov.
          [2 ] US Food and Drug Administration, Silver Spring, MD, USA.
          [3 ] HELIOS Klinikum, Berlin, Germany.
          [4 ] German Breast Group, Neu-Isenburg, Germany.
          [5 ] National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA.
          [6 ] Institut Bergonié INSERM U916 and Université Bordeaux Segalen, Bordeaux, France.
          [7 ] Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, UK.
          [8 ] San Raffaele Scientific Institute, Milan, Italy.
          [9 ] Fondazione Michelangelo, Milan, Italy.
          [10 ] Medstar Washington Hospital Center, Washington, DC, USA.
          [11 ] EORTC Headquarters, Brussels, Belgium.
          [12 ] Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
          [13 ] Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
          [14 ] St Gertrauden Hospital, Berlin, Germany.
          [15 ] MD Anderson Cancer Center Orlando, Orlando, FL, USA.
          [16 ] KarolinskaInstitutet and University Hospital, Stockholm, Sweden.
          [17 ] NN Petrov Research Institute of Oncology, St Petersburg, Russia.
          [18 ] University Women's Hospital, Kiel, Germany.
          [19 ] Jules Bordet Institute, Brussels, Belgium.
          [20 ] Frauenklinik des Universitätsklinikums, Erlangen, Germany.
          [21 ] Universitäts Frauenklinik, Rostock, Germany.
          [22 ] Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA.
          [23 ] Hospital of the Ludwig Maximilian University of Munich, Munich, Germany.
          Article
          S0140-6736(13)62422-8
          10.1016/S0140-6736(13)62422-8
          24529560
          3d72a40e-1c79-4af4-91f7-6d776d3efa49
          Copyright © 2014 Elsevier Ltd. All rights reserved.

          Comments

          Comment on this article